전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-1 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,016 programs
AntibodyLimited DatastaleAmgenPhase 1

blinatumomab and auto-HSCT "sandwich " strategy (blinatumomab and auto-HSCT "sandwich " strategy)

B-cell Acute Lymphoblastic Leukemia · B-cell Acute Lymphoblastic Leukemia

#B-cellAcuteLymphoblasticLeukemia#Antibody#Phase1#monoclonal-antibody#Amgen
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

cTACE+Atirizumab+Bevacizumab (cTACE+Atirizumab+Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleThe Netherlands Cancer InstitutePhase 1

atezolizumab (Tecentriq, carbplatin, cyclophophamide, atezolizumab)

Breast Cancer; Cervix Cancer · Breast Cancer

#BreastCancer#Antibody#Phase1#monoclonal-antibody#CervixCancer+1
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

cisplatin, vinorlebine, cetuximab (cisplatin, vinorlebine, cetuximab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

cisplatine, etoposide, cetuximab (cisplatine, etoposide, cetuximab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleSaglik Bilimleri UniversitesiPreclinical

ranibizumab (Lucentis, dexamethasone implant versus ranibizumab)

Diabetic Macular Edema; Inflammation · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Preclinical#monoclonal-antibody#Inflammation+1
Trials 1Status Active
CGTLimited DatastaleYuLiPhase 2

dual target CAR-T cell therapy (dual target CAR-T cell therapy)

Lymphoma, B-Cell; Relapse/Recurrence · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
ADCLimited DatastaleAstellasPreclinical

pembrolizumab (Keytruda, enfortumab vedotin plus pembrolizumab in first line setting for advanced upper tract urothelial carcinoma)

Advanced Upper Tract Urothelial Carcinoma · Advanced Upper Tract Urothelial Carcinom

#AdvancedUpperTractUrothelialCarc#ADC#Preclinical#antibody-drug-conjugate#Astellas
Trials 1Status Active
AntibodyLimited DatastaleGlaxoSmithKlinePhase 1

GSK3359609 (feladilimab, feladilimab (GSK3359609))

Neoplasms · Neoplasms

#Neoplasms#Antibody#Phase1#monoclonal-antibody#GlaxoSmithKline
Trials 1Status Active
ADCLimited DatastaleCelldex TherapeuticsPhase 2

glembatumumab vedotin and CDX-301 (glembatumumab vedotin and CDX-301)

Melanoma · Melanoma

#Melanoma#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued
ADCLimited DatastaleCelldex TherapeuticsPhase 2

glembatumumab vedotin and varlilumab (glembatumumab vedotin and varlilumab)

Melanoma · Melanoma

#Melanoma#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued
CGTLimited DatastaleInnovative Cellular Therapeutic…Preclinical

gucy2c cart cells (gucy2c cart cells)

Malignant Neoplasms of Digestive Organs · Malignant Neoplasms of Digestive Organs

#MalignantNeoplasmsofDigestiveOrg#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleGilead SciencesPhase 2

the doxorubicin conjugate of milatuzumab (hLL1-DOX, hLL1-DOX (the doxorubicin conjugate of milatuzumab))

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#monoclonal-antibody#Gilead
Trials 1Status Discontinued
CGTLimited DatastaleFollicular Lymphoma FoundationPhase 1

huCART19-IL18-eDHFR cells (huCART19-IL18-eDHFR cells)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleZhujiang HospitalPhase 1

humanized CD19 CAR-T Cells with TLR2 (humanized CD19 CAR-T Cells with TLR2)

B Lymphoblastic Leukemia/Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells (i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells)

Relapsed Neuroblastoma; Refractory Neuroblastoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 1

iC9-CAR.B7-H3 T Cell Therapy (iC9-CAR.B7-H3 T Cell Therapy)

Breast Cancer; Relapse · B7-H3

#B7-H3#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 1

iC9-CAR.B7-H3 T cell infusion (iC9-CAR.B7-H3 T cell infusion)

Pancreas Cancer; Relapse · B7-H3

#B7-H3#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 1

iC9-CAR.B7-H3 T cells (iC9-CAR.B7-H3 T cells)

Ovary Neoplasm; Ovarian Cancer · B7-H3

#B7-H3#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 1

iC9.GD2.CAR.IL-15 T-cells (iC9.GD2.CAR.IL-15 T-cells)

Neuroblastoma; Osteosarcoma · GD2

#GD2#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

49 / 51 pages

← PreviousNext →